Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides.
The aim of this work was to test, evaluate, and compare the immunogenicity of the S3 malarial short synthetic model peptide in Balb/c mice when it was delivered with different adjuvants. Specifically, it studied the adjuvanticity of two different particulate delivery systems, human compatible Montanide((R)) ISA 720 w/o emulsion and poly-lactide-co-glycolide acid microparticles, in terms of the enhancement and sub-set type of the immune response elicited following immunization. Aditionally, conventional aluminum hydroxide gel adjuvant was included as a reference. Aluminum adjuvant failed to improve the lack of immunogenicity of this antigenic peptide on its own. On the other hand, Montanide and microparticles given subcutaneously resulted in effective adjuvants and revealed mixed Th1/Th2 immune responses, with moderate antibody and lymphoproliferative responses, and higher IFN-gamma secretion for Montanide. Hence, microparticles administered intradermally (not possible with Montanide) elicited superior and potent antibody levels, including higher cytophilic isotype (IgG2a), and the greatest limphoproliferation and IFN-gamma levels. The results here presented support the capability and suitability of microparticle delivery systems to reach the adequate adjuvanticity necessary for future malaria vaccine development.
Mata
Elena
E
Pharmacy and Pharmaceutical Technology Laboratory, Pharmacy Faculty, Unversity of the Basque Country (UPV-EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Igartua
Manoli
M
Hernández
Rosa M
RM
Rosas
Jaiver E
JE
Patarroyo
Manuel E
ME
Pedraz
José L
JL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000917:Antibody Formation; D016503:Drug Delivery Systems; D000939:Epitopes; D005260:Female; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000378:metabolism; D019344:Lactic Acid; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008353:Mannitol / Q000031:analogs & derivatives*; D051379:Mice; D008807:Mice, Inbred BALB C; D009829:Oleic Acids; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000939:Epitopes; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D009829:Oleic Acids; D010455:Peptides; D014614:Vaccines, Synthetic; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C001681:mannide monooleate; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008353:Mannitol; D007371:Interferon-gamma